Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Injection site and ocular pain after intravitreal bevacizumab in Ghanaian adults
PACTR202509546846290Recruiting
- Sponsor
- Alex Kweku Addo
- Start
- May 2025
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Randomised, open-label trial of bevacizumab in well-being (4 arms), sponsored by Alex Kweku Addo. Primary endpoint: Association between pain score and site of bevacizumab injection. Started May 2025; status: recruiting.
02
Drugs
bevacizumab
03
Conditions
well-being
Beyond the preview
Go deeper on PACTR202509546846290.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on PACTR202509546846290.